- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01984541
To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.
Biological Standardization of Artemisia Vulgaris Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open, unblinded and non-randomized biological assay. Tehe study design is a slight modification of the recommendations proposed by the Nordic Guidelines.
Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08036
- Hospital Clínic de Barcelona
-
-
Alicante
-
Orihuela, Alicante, Spain, 03314
- Hospital de La Agencia Valenciana de Salud Vega Baja
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Positive clinical history of inhalatory allergy to Artemisia vulgaris. Subject has provided written informed consent, appropriately signed and dated by the subject.
Subject can be male or female of any race and ethinic group. Age major or equal 18 years and ninor or equal 60 years at the study inclusion day.
A positive prick test with a standardized commercially Artemisia vulgaris allergen extract (Wheal medium diameter ≤ 3mm or wheal area ≥ 7 mm2). The skin prick test results are valid if performed within one year prior to the inclusion of the subject in the study.
A positive test for specific IgE to Artemisia vulgaris (CAP-RAST major or equal to 2). IgE results are valid if performed within one year prior to the inclusion of the subject in the study.
Allergy symptoms during the Artemisia vulgaris pollen season.
Exclusion Criteria:
Immunotherapy in the past 5 years with an allergen extract Artemisia vulgaris or other allergen extract that may interfere with the allergene to be tested (for example: Helianthus annuus (sunflower) elatior Ambrosia eiator (ambrosia) or peach.
Use of drugs that may interfere before and after with the skin reactions (for example: antihistamines).
Treatment with any of the following medications: oral tricyclic or tetracyclic antidepressants, beta-blockers, corticosteroids (major 10 mg/daily of prednisone or equivalent).
Women who are pregnant or breastfeeding period and women with positive pregnancy test at Visit 2, before skin prick test.
Dermographism affecting the skin area at the test site at either study visit. Atopic dermatitis affecting the skin area at the test site at either study visit. Urticaria affecting the skin area at the test site at either study visit. Diseases of the immune system relevant clinically, both autoimmune and immunodeficiencies.
Serious diseases not controlled that may increase the risk for the safety of the subjects involved in this study, including, but not limited to the following: heart failure, uncontrolled or severe respiratory diseases, endocrine diseases, clinically relevant kidney or liver diseases or hematological diseases. Participation in any other clinical trial within 30 days (or 5 times the biological half-life of the research of the study product, whichever is longer) prior to the inclusion of the subject in this clinical trial.
Patients with diseases or conditions that limit the use of adrenaline. Severe psychiatric, psychological or neurological disorders. Abuse of alcohol, drugs or medicines in the previous year. Subjects who have received anti-IgE (Omalizumab).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Artemisia vulgaris allergen extract(four concentrations 10, 1, 0,1 y 0,01 mg/ml) Positive Control Negative Control
|
Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Wheal size area (mm2) on the skin at the site of the puncture during the immediate phase.
Time Frame: 15-20 min after aplication
|
15-20 min after aplication
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 6058-PR-PRI-200
- 2013-001310-15 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy to Pollen
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.Completed
-
Laboratorios Leti, S.L.CompletedAllergy to Grass Pollen (Secale Cereale)Spain
-
Laboratorios Leti, S.L.CompletedAllergy to Grass Pollen (Dactylis Glomerata)Spain
-
University of ZurichAlleCureCompletedRhinoconjunctivitis Due to Grass Pollen AllergySwitzerland
-
Assistance Publique - Hôpitaux de ParisIltoo PharmaCompletedAllergic Rhinoconjunctivitis to Birch Pollen | With a Positive Skin Prick Test to Birch PollenFrance
-
MacroArray Diagnostics GmbHCompletedCat Allergy | Grass Pollen Allergy | Birch Pollen Allergy | House Dust Mite Allergy | Bee Venom Allergy | Vespid Venom AllergyAustria
-
Medical University of ViennaAustrian Science Fund (FWF)CompletedBirch Pollen Allergy | Birch Pollen Related Apple AllergyAustria
-
Aston UniversityNational Pollen and Aerobiology Unit, WorcesterCompletedGrass Pollen Ocular AllergyUnited Kingdom
Clinical Trials on Artemisia vulgaris
-
Jill M KolesarArtemiLifeRecruiting
-
Istanbul Medeniyet UniversityUnknown
-
Istanbul Medeniyet UniversityCompleted
-
Nantes University HospitalRecruiting
-
Dr. Behnood AbbasiCompletedType 2 Diabetes MellitusIran, Islamic Republic of
-
Shahid Beheshti UniversityCompletedBlood Pressure | Cardiovascular Risk Factor | Lipid ProfileIran, Islamic Republic of
-
South Valley UniversityNot yet recruitingAcne Vulgaris
-
Instituto Nacional de Ciencias Medicas y Nutricion...TerminatedHypertension | Obesity | Diabetes | Covid19Mexico
-
The Hashemite UniversityCompletedDepression | Sleep | Anxiety | Memory DysfunctionJordan
-
Mbarara University of Science and TechnologyANAMEDCompleted